Education
About Us
Working with TipRanks
Follow Us
ReShape Lifesciences (RSLS)
NASDAQ:RSLS
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.07Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 21, 2025
|% Change Since: -28.21%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.Company Guidance
During the third quarter of 2024, ReShape Lifesciences demonstrated significant financial and operational improvements. Revenue increased by 16.6% compared to the previous quarter and 6.4% year-over-year, marking the third consecutive quarter of growth. The company achieved a gross profit margin of 62.8% for the quarter, with a cumulative margin of 60.3% for the first nine months. Operating expenses were reduced by over 40% compared to the same period last year, and total operating costs for the first nine months were down by 41%. ReShape also reported a non-GAAP adjusted EBITDA of $1.6 million for the quarter, an improvement from a $2.9 million loss in the prior year. In addition, the company secured a supplementary NIH grant of approximately $241,000, bringing total NIH funding to $1.15 million. The company also received approval for its Lap-Band 2.0 FLEX from Health Canada, further expanding its market opportunities.Revenue Growth
Revenue increased by 16.6% in the third quarter over the second quarter and 6.4% over the third quarter of last year.
Cost Reduction Achievements
Achieved over 40% reduction in operating expenses for the first 9 months of the year compared to last year.
Gross Profit Margin Improvement
Gross profit margin increased to 62.8% for the quarter and 60.3% for the first 9 months.
Lap-Band 2.0 FLEX Approval
Received approval for the Lap-Band 2.0 FLEX from Health Canada, supporting global regulatory efforts.
NIH Grant Award
Awarded a $241,000 supplementary grant from NIH, bringing total awards to $1.15 million.
Merger and Asset Sale Agreements
Coordinated merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad, expected to maximize stockholder value.
RSLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RSLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 21, 2025 | $5.92 | $5.12 | -13.51% |
Apr 07, 2025 | $10.83 | $9.48 | -12.47% |
Nov 14, 2024 | $129.25 | $131.00 | +1.35% |
Aug 14, 2024 | $257.96 | $255.34 | -1.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ReShape Lifesciences (RSLS) report earnings?
ReShape Lifesciences (RSLS) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is ReShape Lifesciences (RSLS) earnings time?
ReShape Lifesciences (RSLS) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RSLS EPS forecast?
Currently, no data Available